Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors.

ABSTRACT:

Background

We performed meta-analysis to gather more evidence regarding clinical-molecular subgroups associated with better overall survival (OS) in advanced melanoma treated with checkpoint inhibitors.

Materials and methods

We performed a systematic search of PubMed, Scopus, Cochrane Library, and clinical trial.gov. Randomized clinical trials that compared a checkpoint inhibitor (nivolumab or pembrolizumab) with investigator choice chemotherapy or ipilimumab were included in our study. Hazard ratios (HR) and confidence interval (CI) were calculated for progression-free survival (PFS) and OS for each subgroup using generic inverse model along with the random effect method.

Results

A total of 6 clinical trials were eligible for the meta-analysis. OS was prolonged in wi

SUBMITTER: Badami S 

PROVIDER: S-EPMC6077519 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature